


**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT  
Nathalie GarconFILING DATE  
16 April 2001GROUP  
1648**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
32	6,932,972	23 Aug. 2005	Stephenne, et al.			
	5,776,468	7 July 1998	Houser, et al.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
32	EP 0511855	29 Apr. 1992	EP				
32	EP 0278940	25 Jan. 1988	EP				
32	EP 0414374	19 July 1990	EP				
32	EP 0198474	15 Apr. 1986	EP				
32	EP 0304578	22 June 1988	EP				
32	EP 0576478	17 Mar. 1992	EP				
32	EP 0689454	14 Mar. 1994	EP				
32	EP 0633784	24 Mar. 1993	EP				
32	EP 0226846AB1	25 Nov. 1986	EP				
32	EP 0299108AB1	17 July 1987	EP				
32	EP 1231264 (GB 9515478.7)	4 Aug. 2000	EP				
32	EP 00/02920	18 Dec. 1978	EP				
32	EP 00/08728	20 Aug. 1979	EP				
32	EP 01/11984	17 Dec. 1983	EP				
32	GB 2220211	22 Jun 1989	UK				
	WO 93/019780	14 Oct. 1993	PCT				
32	WO 88/09797 (EP 0362278)	15 Dec. 1988	PCT				
32	GB 9805105 (WO 99/45957)	16 Sep. 1999	PCT				
32	WO 91/14703	3 Oct. 1991	PCT				
32	WO 01/17550A2	15 Mar. 2001	PCT				
32	WO 96/33739	31 Oct. 1996	PCT				
32	WO 96/02555	1 Feb. 1996	PCT				
32	WO 93/10152	27 May 1993	PCT				
32	WO 90/01496	22 Feb. 1990	PCT				
32	WO 92/16231	1 Oct. 1992	PCT				

32	WO 99/10375	4 Mar. 1999	PCT				
32	WO 93/24148	9 Dec. 1993	PCT				
32	WO 01/17551	15 Mar. 2001	PCT				
	WO 94/21292	29 Sep. 1994	PCT				

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45158X1	SERIAL NO. 09/807,657
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Nathalie Garcon	
		FILING DATE 16 April 2001	GROUP 1648

**FOREIGN PATENT DOCUMENTS**


		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

32	Van den Eynde, et al., "Tumor Antigens Recognized by T Lymphocytes," <i>Int J. Clin Res</i> , 1997 27:81-86
32	Correale, et al., "In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen," <i>Journal of the National Cancer Institute</i> , 1997 89:293-300
32	Robbins, et al., "Human Tumor Antigens Recognized by T Cells," <i>Current Opinion in Immunology</i> , 1996 8:628-636
32	Andre, et al., "Inactivated Candidate Vaccines for Hepatitis A," <i>Melnick JL (ed.): Prog Med Virol, Basel, Karger</i> , 1990 37:72-95
32	Eddleston, "Modern Vaccines," <i>The Lancet</i> , 1990 335:1142-1145
32	Dalsgaard, "Saponin Adjuvants," <i>Springer-Verlag</i> , 1974 44:243-254
32	Tiollais, et al., "The Hepatitis B Virus," <i>Nature</i> , 1985 317:489-495
32	Harford, et al., "Expression of Hepatitis B Surface Antigen in Yeast," <i>Develop. Biol. Standard</i> , 1983 54:125-130
32	Cregg, et al., "High-Level Expression and Efficient Assembly of Hepatitis B Surface Antigen in the Methylophilic Yeast, <i>Pichia Pastoris</i> ," <i>Biotechnology</i> 1987 5:479-485
32	Vogel, et al., "A Compendium of Vaccine Adjuvants and Excipients," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995 Chapter 7:141-228
32	Newman, et al., "Adjuvant Formulation Concerns," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 1, 4.6:26-27
32	Gupta, et al., "Adjuvant Properties of Aluminum and Calcium Compounds," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 8:229-248

32	Hem, et al., "Structure and Properties of Aluminum-Containing Adjuvants," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 9:249-276
32	Ulrich, et al., "Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions," <i>Vaccine Design - the Subunit and Adjuvant Approach</i> , Plenum Press, 1995, Chapter 21:495-524
32	Purcell, "Approaches to Immunization against Hepatitis A Virus," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:41-46
32	Day, et al., "Evaluation of the Human B Lymphocyte Response to Hepatitis A Virus," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:69-71
32	Andre, "Development of a Vaccine against Hepatitis A," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:85-87
32	Sjogren, et al., "Inactivated Hepatitis A Vaccine in Adults: Comparison of Dose Schedules and Evaluation of Different Preparations," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:88-90
32	Ellerbeck, et al., "Safety and Immunogenicity of an Inactivated Hepatitis A Virus Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:91-93
32	Lewis, et al., "Use of a Live, Attenuated Hepatitis A Vaccine to Prepare a Highly Purified, Formalin-inactivated Hepatitis A Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:94-97
32	Ambrosch, et al., "Comparison of HAV Antibodies Induced by Vaccination, Passive Immunization, and Natural Infection", <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:98-100
32	Karayiannis, et al., "Vaccination of Tamarins with a Recombinant Vaccinia-Hepatitis A Virus Protects against HAV Infection," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:101-104
32	Weitz, et al., "Empty Hepatitis A Virus Particles in Vaccines," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:104-108
32	Heinricy, et al., "Schedule-dependent Immune Response to Hepatitis A Vaccination," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:108-110
32	Mao, et al., "Further Studies of Attenuated Live Hepatitis A Vaccine (H2 Strain) in Humans," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 2:110-111
32	Fuchs, et al., "Protection from Infection with Woodchuck Hepatitis Virus (WHV) by Immunization with Recombinant Core Protein of WHV and HGV," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 3:267-270
32	Margolis, et al., "Immunization Strategies for the Control of Hepatitis A in the United States," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:724-726
32	Mahoney, "Cost of Production of Plasma-derived Hepatitis B Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:730-731

32	De Knecht, et al., "Low-Dose Hepatitis B Vaccination with Recombinant Vaccine in Medical Students," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:741-744
32	Lee, et al., "Immunogenicity and Protective Efficacy on Low-Dose Hepatitis B Vaccine in Newborns of HBsAg-Carrier Mothers," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:744-746
32	Yamauchi, et al., "Reduced Immunogenicity of Hepatitis B Vaccine in Patients with Chronic Non-A, Non-B (Type C) Hepatitis," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:747-748
32	Yeoh, et al., "Determinants of Immunogenicity and Efficacy of Hepatitis B Vaccine in Infants," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:749-752
32	Lelie, et al., "Prevention of the Hepatitis B Virus Carrier State in Infants of Mothers with High and Low Serum Levels of HBV-DNA," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:753-756
32	Boxall, et al., "HBV-DNA Levels in Hepatitis B Carrier Mothers; Relationship with Protection against Perinatal Transmission by Vaccine," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:757-759
32	Hwang, et al., "Five-Year Follow-up of HBV Vaccination with Plasma-derived Vaccine in Neonates: Evaluation of Immunogenicity and Efficacy against Perinatal Transmission," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:759-761
32	Wainwright, et al., "Duration of Immunogenicity and Efficacy of Hepatitis B Vaccine in a Yupik Eskimo Population-Preliminary Results of an 8-Year Study," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:762-766
32	Hadler, et al., "Evaluation of Long-Term Protection by Hepatitis B Vaccine for Seven to Nine Years in Homosexual Men," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:766-768
32	Milich, et al., "Importance of Subtype in the Immune Response to the PreS2 Region," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:768-773
32	Hattum, et al., "In Vitro Anti-HBs Production by Individual B Cells of Responders to Hepatitis B Vaccine Who Subsequently Lost Antibody," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:774-776
32	Lee, et al., "The Second Booster for the Previously Hepatitis B Vaccine-immunized High-Risk Children," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:776-778
32	Takahashi, et al., "Identification of Low-Level Hepatitis B Viral Genome in Hepatitis B Vaccine Nonresponders in Japan," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:779-781
32	Sciariada, et al., "Immune Response to Hepatitis B Vaccine in Persons with Anti-HBc Alone," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:782-784

32	Schödel, et al., "Oral Immunization of Mice with Hepatitis B Virus B Cell and T Cell Epitopes Expressed in Salmonella Vaccine Strains," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 9:784-787
32	Fay, et al., "Strategies for Implementing Successful Hepatitis B Vaccination Programs," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:831-833
32	Milich, "A Synthetic PreS2 Immunogen," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:840-844
32	Michel, et al., "Hepatitis B Virus Surface Antigen (HBsAg) as Carrier for Foreign Antigenic Determinants," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:844-846
32	Robinson, et al., "Hepatitis B Virus Antigens Expressed by Live Salmonella Vaccine Strains Elicit Humoral and Cellular Immune Responses in Mice," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:847-849
32	Tong, et al., "Immunoprophylaxis of Neonates against Hepatitis B," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:849-855
32	Grob, et al., "Unresolved Issues in Hepatitis B Immunization," <i>Viral Hepatitis and Liver Disease</i> , Williams & Wilkins, 1990, Section 10:856-860
EXAMINER 	
DATE CONSIDERED 10/6/05	
EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\Reid\patapps\b45158\pto 1449 form.doc



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45158X1	SERIAL NO. 09/807,657
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Nathalie Garcon	
		FILING DATE 16 April 2001	GROUP 1648

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
32	10/540,099	18-Dec-2003	Dubin et al			
32	10/508,222	17-Mar-2003	Wettendorff, et al.			
	10/070,479	07-Sept-2000	Wettendorff, et al.			
32	08/894,643	15-Feb-1996	Garcon, et al.			
32	10/465,763	19-Jun-2003	Garcon, et al.			
32	08/525,638	14-Mar-1994	Hauser, et al.			
32	09/661,926	14-Sep-2000	Slaoui, et al.			
32	09/730,930	6-Dec-2000	Claude et al.			
32	09/405,469	24-Sep-1999	Garcon, et al.			
32	10/760,938	20-Jan-2004	Slaoui, et al			
32	11/158,652	22-Jun-2005	Slaoui, et al			
32	09/646,205	27-Oct-2000	Slaoui, et al.			
32	08/307,668	29-Sep-1994	Garcon, et al.			
32	08/440,872	15-May-1995	Garcon, et al.			
32	5,972,346	26 Oct. 1999	Garcon, et al.			
32	6,893,644	17 May 2005	Garcon, et al.			
	5,776,468	07 July 1998	Hauser, et al.			
32	6,692,752	14 Sept. 2000	Slaoui, et al.			

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
32	WO 2004/056389	08 July 2004	PCT				
32	WO 2003/077942	25 Sept. 2003	PCT				
32	WO 1993/19780	14 Oct. 1993	PCT				
	WO 1996/26741	26 Oct. 1999	PCT				
32	WO 1994/21292	07 July 1998	PCT				
32	WO 2000/15255	23 Mar. 2000	PCT				

EXAMINER 	DATE CONSIDERED 10/16/05
--------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45158X1	SERIAL NO. 09/807,657
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		APPLICANT Nathalie Garcon	
		FILING DATE 16 April 2001	GROUP 1648

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
32	10/540,099	18-Dec-2003	Dubin et al			
32	10/508,222	17-Mar-2003	Wettendorff, et al.			
32	10/070,479	07-Sept-2000	Wettendorff, et al.			
32	08/894,643	15-Feb-1996	Garcon, et al.			
32	10/465,763	19-Jun-2003	Garcon, et al.			
32	08/525,638	14-Mar-1994	Hauser, et al.			
32	09/661,926	14-Sep-2000	Slaoui, et al.			
32	09/730,930	6-Dec-2000	Claude et al.			
32	09/405,469	24-Sep-1999	Garcon, et al.			
32	10/760,938	20-Jan-2004	Slaoui, et al			
32	11/158,652	22-Jun-2005	Slaoui, et al			
32	09/646,205	27-Oct-2000	Slaoui, et al.			
32	08/307,668	29-Sep-1994	Garcon, et al.			
32	08/440,872	15-May-1995	Garcon, et al.			
32	5,972,346	26 Oct. 1999	Garcon, et al.			
32	6,893,644	17 May 2005	Garcon, et al.			
32	5,776,468	07 July 1998	Hauser, et al.			
32	6,692,752	14 Sept. 2000	Slaoui, et al.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
32	WO 2004/056389	08 July 2004	PCT				
32	WO 2003/077942	25 Sept. 2003	PCT				
32	WO 1993/19780	14 Oct. 1993	PCT				
32	WO 1996/26741	26 Oct. 1999	PCT				
32	WO 1994/21292	07 July 1998	PCT				
32	WO 2000/15255	23 Mar. 2000	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.